Biologics-Based Therapy for the Treatment of Rheumatoid Arthritis
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Rheumatoid arthritis (RA) remains a major clinical problem, but treatments involving biologics have revolutionized its management. They target pathogenically relevant cytokines such as tumor necrosis factor and immune cells such as B cells. In RA, biologics reduce joint inflammation, limit erosive damage, decrease disability, and improve quality of life. Infections are the main risk associated with their use. Because of the high prices of biologics, their cost-effectiveness is a matter of debate. They are mainly coadministered with disease-modifying drugs such as methotrexate when the latter are found to achieve insufficient disease control on their own.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jobanputra, P., Barton, P., Bryan, S., & Burls, A. (2002) · Health Technology Assessment · doi:10.3310/hta6210 · Cited by 126
Cited by
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Schwartz, D. M., Bonelli, M., Gadina, M., & O'Shea, J. J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.167 · Cited by 648
Taurine and Inflammatory Diseases
Marcinkiewicz, J., & Kontny, E. (2014) · Amino Acids · doi:10.1007/s00726-012-1361-4 · Cited by 531
Al-Riyami, L., Pineda, M. A., Rzepecka, J., Huggan, J. K., Khalaf, A. I., Suckling, C. J., Scott, F. J., Rodgers, D. T., Harnett, M. M., & Harnett, W. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401251p · Cited by 94
Mitogen-Activated Protein Kinases as Therapeutic Targets for Rheumatoid Arthritis
Paunovic, V., & Harnett, M. M. (2013) · Drugs · doi:10.1007/s40265-013-0014-6 · Cited by 61
Metadata
- Authors
- Scott, D. L.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2011-12-14
- Volume
- 91
- Issue
- 1
- Pages
- 30-43
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2170521635
- Cited by
- 173
- References
- 1
- FWCI
- 12.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.